Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease
Eva Martínez‐Pinilla, David Aguinaga, Gemma Navarro, et al.
Molecular Neurobiology (2019) Vol. 56, Iss. 8, pp. 5900-5910
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review
Ruwini Cooray, Veer Bala Gupta, Cenk Suphioglu
Molecular Neurobiology (2020) Vol. 57, Iss. 11, pp. 4878-4890
Open Access | Times Cited: 111
A Guide to Targeting the Endocannabinoid System in Drug Design
Adam Stasiulewicz, Katarzyna Znajdek, Monika Grudzień, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2778-2778
Open Access | Times Cited: 102
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 574-601
Open Access | Times Cited: 11
Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
Sarah Beggiato, Maria Cristina Tomasini, Luca Ferraro
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 72
Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases—focusing on FAAH/MAGL inhibitors
Siyu Ren, Zhen‐Zhen Wang, Yi Zhang, et al.
Acta Pharmacologica Sinica (2020) Vol. 41, Iss. 10, pp. 1263-1271
Open Access | Times Cited: 66
Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease
Mengya Wang, Huayuan Liu, Zegang Ma
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 23
Heteromers Formed by GPR55 and Either Cannabinoid CB1 or CB2 Receptors Are Upregulated in the Prefrontal Cortex of Multiple Sclerosis Patients
Carlota Menéndez-Pérez, Rafael Rivas‐Santisteban, Eva del Valle, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4176-4176
Open Access | Times Cited: 4
Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain
Stefania Nobili, Laura Micheli, Elena Lucarini, et al.
Pharmacology & Therapeutics (2024) Vol. 258, pp. 108649-108649
Open Access | Times Cited: 4
Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies
Vamsi Reddy, Dayton Grogan, Meenakshi Ahluwalia, et al.
The EPMA Journal (2020) Vol. 11, Iss. 2, pp. 217-250
Open Access | Times Cited: 34
The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling
Argelia Calvillo-Robledo, Rodolfo Daniel Cervantes‐Villagrana, Paula Morales, et al.
Life Sciences (2022) Vol. 301, pp. 120596-120596
Open Access | Times Cited: 19
Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
Tapan Behl, Gagandeep Kaur, Simona Bungău, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6235-6235
Open Access | Times Cited: 27
The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease
Qi-wen Han, Yu‐He Yuan, Nai‐Hong Chen
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 96, pp. 109745-109745
Closed Access | Times Cited: 27
The cannabinoid CB1 receptor interacts with the angiotensin AT2 receptor. Overexpression of AT2-CB1 receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats
Rafael Rivas‐Santisteban, Jaume Lillo, Iu Raïch, et al.
Experimental Neurology (2023) Vol. 362, pp. 114319-114319
Open Access | Times Cited: 7
Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs
Rafael Franco, Gemma Navarro
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Modulation of neuroinflammation and oxidative stress by targeting GPR55 – new approaches in the treatment of psychiatric disorders
Matthias Apweiler, Soraya Wilke Saliba, Lu Sun, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 12, pp. 3779-3788
Open Access | Times Cited: 2
Regulation of Expression of Cannabinoid CB2 and Serotonin 5HT1A Receptor Complexes by Cannabinoids in Animal Models of Hypoxia and in Oxygen/Glucose-Deprived Neurons
Jaume Lillo, Iu Raïch, Laura Silva, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9695-9695
Open Access | Times Cited: 11
Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Sonia Burgaz, Concepción García, Claudia Gonzalo‐Consuegra, et al.
Molecules (2021) Vol. 26, Iss. 24, pp. 7643-7643
Open Access | Times Cited: 15
Cuprizone-Induced Neurotoxicity in Human Neural Cell Lines Is Mediated by a Reversible Mitochondrial Dysfunction: Relevance for Demyelination Models
Eva Martínez‐Pinilla, Núria Rubio-Sardón, Sandra Villar‐Conde, et al.
Brain Sciences (2021) Vol. 11, Iss. 2, pp. 272-272
Open Access | Times Cited: 14
The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors
Rafael Franco, Paula Morales, Gemma Navarro, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 8
Potential Protective Effects of Pungent Flavor Components in Neurodegenerative Diseases
F.-Q. Guo, Xiangnan Qin, Jian Mao, et al.
Molecules (2024) Vol. 29, Iss. 23, pp. 5700-5700
Open Access | Times Cited: 1
Presynaptic nigral GPR55 receptors stimulate [3H]‐GABA release through [3H]‐cAMP production and PKA activation and promote motor behavior
Rodolfo Sánchez‐Zavaleta, José Arturo Ávalos‐Fuentes, Antonio Valentín González‐Hernández, et al.
Synapse (2022) Vol. 76, Iss. 11-12
Closed Access | Times Cited: 7
Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats
Felipe Patricio, Eliud Morales Dávila, Aleidy Patricio-Martínez, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 5
Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum
Eva Martínez‐Pinilla, Alberto J. Rico, Rafael Rivas‐Santisteban, et al.
Annals of the New York Academy of Sciences (2020) Vol. 1475, Iss. 1, pp. 34-42
Closed Access | Times Cited: 7
Cannabinoid receptor subtype influence on neuritogenesis in human SH-SY5Y cells
Erica L. Lyons, Sandra Leone‐Kabler, Alexander L. Kovach, et al.
Molecular and Cellular Neuroscience (2020) Vol. 109, pp. 103566-103566
Open Access | Times Cited: 7
BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis
Marta Gómez‐Almería, Sonia Burgaz, Carlos Costas‐Insua, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12533-12533
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top